Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue, to nearly $21 million.
Adaptive Biotech revenue rises 65% to $21M, loss widens amid big COVID-19 immune partnerships
More Stories
Brazil rolls out COVID-19 vaccination plan
First Pfizer COVID-19 vaccine shipments to be delivered to US distribution sites starting Monday
CDC advisory panel recommends Covid-19 vaccine for people 16 and over